

Induction of Abortion (Unspecified Gestation)

References to July 2007

Review Articles

Studies continue in methotrexate use. *Contracept.Technol.Update.* 1998;**19**:114, 119.

Cutting unsafe abortions. *Afr.Health* 1998;**20**:46.

Summary of evidence and research needs on the use of mifepristone in fertility regulation: consensus from the conference. *Contraception* 2003;**68**:401-7.

[Anon]. Urgent need for standardised misoprostol regimens. *Reproductive Health Matters* 2002;**10**:202.

[Anon]. Oral misoprostol alone is not reliable for medical abortion. *Reproductive Health Matters* 2006;**14**:237.

Aubeny E. [Trends since 1989, in France, of induced abortions by mifepristone (RU486) combined with a prostaglandin analogue]. *Contracept.Fertil.Sex* 1997;**25**:777-81.

Bardin CW, Robbins A, O'Connor BM, Spitz I. Medical abortion. *Curr.Ther.Endocrinol.Metab* 1997;**6**:305-11.

Beal MW. Update on medication abortion. *Journal of Midwifery & Womens Health* 2007;**52**:23-30.

Blanchard K, Clark S, Winikoff B, Gaines G, Kabani G, Shannon C. Misoprostol for women's health: a review. *Obstet.Gynecol.* 2002;**99**:316-32.

Bygdeman M. [Treatment in miscarriage and abortion. Widened use of drugs has many advantages]. *Lakartidningen* 1994;**91**:1396-7.

Capilla MC, Bermejo VT. [Efficacy and safety of misoprostol in obstetrics]. *Farm.Hosp.* 2005;**29**:177-84.

da Silva DP, Knop FP, Mengue SS. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. *Reprod.Toxicol.* 2006;**22**:666-71.

Espinoza H, Ellertson C, Garcia S, Schiavon R, Langer A. [Medical methods for pregnancy termination. A review of literature and its potential role in Mexico and Latin America]. *Gac.Med.Mex.* 2002;**138**:347-56.

Fiala C, Gemzel-Danielsson K. Review of medical abortion using mifepristone in combination with a prostaglandin analogue. *Contraception* 2006;**74**:66-86.

- Fielding SL, Lee SS, Schaff EA. Professional considerations for providing mifepristone-induced abortion. *Nurse Pract.* 2001;**26**:44-54.
- Gemzell-Danielsson K, Bygdeman M, Aronsson A. Studies on uterine contractility following mifepristone and various routes of misoprostol. *Contraception* 2006;**74**:31-5.
- Goldberg AB, Carusi DA, Meckstroth KR. Misoprostol in gynecology. *Curr.Womens Health Rep.* 2003;**3**:475-83.
- Grimes DA. Medical abortion: public health and private lives. *Am.J.Obstet.Gynecol.* 2000;**183**:S1-S2.
- Harper CC, Blanchard K, Grossman D, Henderson JT, Darney PD. Reducing maternal mortality due to elective abortion: Potential impact of misoprostol in low-resource settings. *Int.J.Gynaecol.Obstet.* 2007;**98**:66-9.
- Marions L. Mifepristone dose in the regimen with misoprostol for medical abortion. *Contraception* 2006;**74**:21-5.
- McGuffey EC. Contraceptive options for the 1990s. *J.Am.Pharm.Assoc.(Wash.)* 1997;**NS37**:149-53.
- Miller S, Lehman T, Campbell M, Hemmerling A, Anderson SB, Rodriguez H *et al.* Misoprostol and declining abortion-related morbidity in Santo Domingo, Dominican Republic: a temporal association. *BJOG.* 2005;**112**:1291-6.
- Petersen MB, Rorbye C, Nilas L. [Large variation in clinical regimens use to induce medical abortion in Denmark]. *Ugeskr.Laeger* 2003;**165**:2187-90.
- Peyron R, Ulmann A, Baulieu EE. [Mifepristone (RU 486): present status, prospectives]. *Presse Med.* 1995;**24**:295-8.
- Pohls UG, Steck T, Dietl J. [Fetal complications after failed pregnancy termination in the first trimester]. *Z.Geburtshilfe Neonatol.* 2000;**204**:153-7.
- Pohls UG, Steck T, Dietl J. Fetal complications associated with unsuccessful attempts at termination of pregnancy. *Zeitschrift fur Geburtshilfe und Neonatologie* 2000;**204**:153-7.
- Potts M. Non-surgical abortion: who's for methotrexate? *Lancet* 1995;**346**:655-6.
- Potts M. Meeting the contraceptive and AIDS prevention needs of people living on a dollar a day. *Reprod.Fertil.Dev.* 2001;**13**:739-47.
- Pradhan P. Making unsafe abortion safe: medical method. *Nepal.Med.Coll.J.* 2004;**6**:147-51.

Rogo K. Improving technologies to reduce abortion-related morbidity and mortality. *Int.J.Gynaecol.Obstet.* 2004;**85 Suppl 1**:S73-S82.

Rosenman S, Kleinman G. Cervical pregnancy: two case reports. *Conn.Med.* 2002;**66**:71-2.

Sarkar NN. Mifepristone: bioavailability, pharmacokinetics and use-effectiveness. *Eur.J.Obstet.Gynecol.Reprod.Biol.* 2002;**101**:113-20.

Schaff E. Evidence for shortening the time interval of prostaglandin after mifepristone for medical abortion. *Contraception* 2006;**74**:42-4.

Winikoff B, Ellertson C, Clark S. Analysis of failure in medical abortion. *Contraception* 1996;**54**:323-7.

Zou Y, Li YP, Lei ZW, Lu L, Jiang S, Li Q. [Side effect of mifepristone in combination with misoprostol for medical abortion]. *Zhonghua Fu Chan Ke.Za Zhi.* 2004;**39**:39-42.

Clinical Studies

Randomised Controlled Trials

Dahiya K, Madan S, Hooda R, Sangwan K, Khosla AH. Evaluation of the efficacy of mifepristone/misoprostol and methotrexate/misoprostol for medical abortion. *Indian J.Med.Sci.* 2005;**59**:301-6.

Fan GS, Jin L, Xi S, Li H. [Clinical observation of propofol combined with misoprostol for painless induced abortion]. *Zhonghua Yi.Xue.Za Zhi.* 2005;**85**:1106-8.

Foy R, Penney GC, Grimshaw JM, Ramsay CR, Walker AE, MacLennan G *et al.* A randomised controlled trial of a tailored multifaceted strategy to promote implementation of a clinical guideline on induced abortion care. *BJOG.* 2004;**111**:726-33.

Li R, Wang Z, Wu R. [Study on decidual and villous cells apoptosis and its control gene in medical abortion]. *Zhonghua Fu Chan Ke.Za Zhi.* 1999;**34**:281-3.

Moran T, Deutsch R. Methotrexate/misoprostol vs. a more standard approach for termination of pregnancies of undetermined location: a randomized, controlled trial. *J.Reprod.Med.* 2005;**50**:784-92.

Pongsatha S, Tongsong T. Intravaginal misoprostol for pregnancy termination. *Int.J.Gynaecol.Obstet.* 2004;**87**:176-7.

Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. *Contraception* 2005;**71**:22-5.

Tang OS, Xu J, Cheng L, Lee SW, Ho PC. The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol: a randomized placebo controlled trial. *Hum.Reprod.* 2002;**17**:99-102.

Wiebe E. Pain control in medical abortion. *Int.J.Gynaecol.Obstet.* 2001;**74**:275-80.

Wiebe ER. Abortion induced with methotrexate and misoprostol: a comparison of various protocols. *Contraception* 1997;**55**:159-63.

Wiebe ER. Oral methotrexate compared with injected methotrexate when used with misoprostol for abortion. *Am.J.Obstet.Gynecol.* 1999;**181**:149-52.

Observational Studies

Women use illicit drug to induce abortion. *Indian Med.Trib.* 1993;**1**:11.

Women find mifepristone safe, acceptable method. *Contracept.Technol.Update.* 1998;**19**:113-4.

[Anon]. Clostridium sordellii toxic shock syndrome after medical abortion with mifepristone and intravaginal misoprostol - United States and Canada, 2001-2005 (Reprinted from MMWR, vol 54, pg 724, 2005). *Jama-Journal of the American Medical Association* 2005;**294**:1894.

[Anon]. Home-use of misoprostol highly acceptable for Swedish women and their partners. *Reproductive Health Matters* 2005;**13**:165.

Adam MP, Manning MA, Beck AE, Kwan A, Enns GM, Clericuzio C *et al.* Methotrexate/misoprostol embryopathy: report of four cases resulting from failed medical abortion. *Am.J.Med.Genet.A* 2003;**123**:72-8.

Akin A, Blum J, Ozalp S, Onderoglu L, Kirca U, Bilgili N *et al.* Results and lessons learned from a small medical abortion clinical study in Turkey. *Contraception* 2004;**70**:401-6.

Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases. *BJOG.* 2002;**109**:1281-9.

Austin J, Ford MD, Rouse A, Hanna E. Acute intravaginal misoprostol toxicity with fetal demise. *J.Emerg.Med.* 1997;**15**:61-4.

Beckman LJ, Harvey SM. Experience and acceptability of medical abortion with mifepristone and misoprostol among U.S. women. *Womens Health Issues* 1997;**7**:253-62.

Blanchard K, Schaffer K, McLeod S, Winikoff B. Medication abortion in the private sector in South Africa. *Eur.J.Contracept.Reprod.Health Care* 2006;**11**:285-90.

Blum J, Hajri S, Chelli H, Mansour FB, Gueddana N, Winikoff B. The medical abortion experiences of married and unmarried women in Tunis, Tunisia. *Contraception* 2004;**69**:63-9.

Briozzo L, Vidiella G, Rodriguez F, Gorgoroso M, Faundes A, Pons JE. A risk reduction strategy to prevent maternal deaths associated with unsafe abortion. *Int.J.Gynaecol.Obstet.* 2006;**95**:221-6.

Castle MA, Harvey SM, Beckman L, Coeytaux F, Garrity JM. Listening and learning from women about mifepristone: implications for counseling and health education. *Womens Health Issues* 1995;**5**:130-8.

Clark S, Ellertson C, Winikoff B. Is medical abortion acceptable to all American women: the impact of sociodemographic characteristics on the acceptability of mifepristone-misoprostol abortion. *J.Am.Med.Womens Assoc.* 2000;**55**:177-82.

Coelho HL, Teixeira AC, Santos AP, Forte EB, Morais SM, La Vecchia C *et al.* Misoprostol and illegal abortion in Fortaleza, Brazil. *Lancet* 1993;**341**:1261-3.

Cowett AA, Cohen LS, Lichtenberg ES, Stika CS. Ultrasound evaluation of the endometrium after medical termination of pregnancy. *Obstet.Gynecol.* 2004;**103**:871-5.

Coyaji K, Elul B, Krishna U, Otiv S, Ambardekar S, Bopardikar A *et al.* Mifepristone abortion outside the urban research hospital setting in India. *Lancet* 2001;**357**:120-2.

Creinin MD, Jerald H. Success rates and estimation of gestational age for medical abortion vary with transvaginal ultrasonographic criteria. *Am.J.Obstet.Gynecol.* 1999;**180**:35-41.

Cronemberger MF, Castro Moreira JB, Brunoni D, Mendonca TS, Alvarenga EH, Rizzo AM *et al.* Ocular and clinical manifestations of Mobius' syndrome. *J.Pediatr.Ophthalmol.Strabismus* 2001;**38**:156-62.

Dagousset I, Fourrier E, Aubeny E, Taurelle R. [Use of Misoprostol for medical abortion: a trial of the acceptability for home use]. *Gynecol.Obstet.Fertil.* 2004;**32**:28-33.

Daisley H. Case reports 1. Maternal mortality following the use of misoprostol. *Medicine Science and the Law* 2000;**40**:78-82.

- Daisley H, Jr. Maternal mortality following the use of misoprostol. *Med.Sci.Law* 2000;**40**:78-82.
- de Souza AI, Cecatti JG, Ferreira LOC, Santos LC. Reasons for hospitalization due to abortion and pregnancy termination. *Journal of Tropical Pediatrics* 1999;**45**:31-6.
- Ellertson C, Simonds W, Winikoff B, Springer K, Bagchi D. Providing mifepristone-misoprostol medical abortion: the view from the clinic. *J.Am.Med.Womens Assoc.* 1999;**54**:91-6.
- Elul B, Pearlman E, Sorhaindo A, Simonds W, Westhoff C. In-depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol. *J.Am.Med.Womens Assoc.* 2000;**55**:169-72.
- Espinoza H, Abuabara K, Ellertson C. Physicians' knowledge and opinions about medication abortion in four Latin American and Caribbean region countries. *Contraception* 2004;**70**:127-33.
- Faundes A, Santos LC, Carvalho M, Gras C. Post-abortion complications after interruption of pregnancy with misoprostol. *Adv.Contracept.* 1996;**12**:1-9.
- Fielding SL, Edmunds E, Schaff EA. Having an abortion using mifepristone and home misoprostol: a qualitative analysis of women's experiences. *Perspect.Sex Reprod.Health* 2002;**34**:34-40.
- Fischer M, Bhatnagar J, Guarner J, Reagan S, Hacker JK, Van Meter SH *et al.* Fatal toxic shock syndrome associated with *Clostridium sordellii* after medical abortion. *N.Engl.J.Med.* 2005;**353**:2352-60.
- Fonseca W, Misago C, Correia LL, Parente JA, Oliveira FC. [Determinants of induced abortion among poor women admitted to hospitals in a locality of northeastern Brazil]. *Rev.Saude Publica* 1996;**30**:13-8.
- Fonseca W, Misago C, Correia LL, Parente JAM, Oliveira FC. Determinants of induced abortion among poor women admitted to hospitals in locality of the region, northeast Brazil. *Revista de Saude Publica* 1996;**30**:13-8.
- Fontenelle L, Araujo APDC, Fontana RS. Moebius syndrome: case report. *Arquivos de Neuro-Psiquiatria* 2001;**59**:812-4.
- Ganatra B, Manning V, Pallipamulla SP. Availability of medical abortion pills and the role of chemists: a study from Bihar and Jharkhand, India. *Reprod.Health Matters.* 2005;**13**:65-74.
- Gonzalez CH, Marques-Dias MJ, Kim CA, Sugayama SM, Da Paz JA, Huson SM *et al.* Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. *Lancet* 1998;**351**:1624-7.

- Gonzalez CH, Marques-Dias MJ, Kim CA, Paz JA, Sugayama SMM, Valente M. Misoprostol embryopathy: clinical evaluations of 13 patients with congenital hydrocephaly. *American Journal of Human Genetics* 2002;**71**:279.
- Gould H, Ellertson C, Corona G. Knowledge and attitudes about the differences between emergency contraception and medical abortion among middle-class women and men of reproductive age in Mexico City. *Contraception* 2002;**66**:417-26.
- Graf WD, Shepard TH. Uterine contraction in the development of Mobius syndrome. *J. Child Neurol.* 1997;**12**:225-7.
- Haimov-Kochman R, Arbel R, Sciaky-Tamir Y, Brzezinski A, Laufer N, Yagel S. Risk factors for unsuccessful medical abortion with mifepristone and misoprostol. *Acta Obstet. Gynecol. Scand.* 2007;**86**:462-6.
- Hajri S, Blum J, Gueddana N, Saadi H, Maazoun L, Chelli H *et al.* Expanding medical abortion in Tunisia: women's experiences from a multi-site expansion study. *Contraception* 2004;**70**:487-91.
- Harvey SM, Beckman LJ, Satre SJ. Choice of and satisfaction with methods of medical and surgical abortion among US clinic patients. *Family Planning Perspectives* 2001;**33**:212-6.
- Harvey SM, Nichols MD. Development and evaluation of the abortion attributes questionnaire. *Journal of Social Issues* 2005;**61**:95-107.
- Harwood B, Meckstroth KR, Mishell DR, Jain JK. Serum beta-human chorionic gonadotropin levels and endometrial thickness after medical abortion. *Contraception* 2001;**63**:255-6.
- Hassoun D, Perin I. [Ambulatory medical abortion performed in a family planning center]. *J. Gynecol. Obstet. Biol. Reprod. (Paris)* 2006;**35**:483-9.
- Hedley A, Ellertson C, Trussell J, Turner AN, Aubeny E, Coyaji K *et al.* Accounting for time: insights from a life-table analysis of the efficacy of medical abortion. *Am. J. Obstet. Gynecol.* 2004;**191**:1928-33.
- Hedley A, Trussell J, Turner AN, Coyaji K, Ngoc NT, Winikoff B *et al.* Differences in efficacy, differences in providers: results from a hazard analysis of medical abortion. *Contraception* 2004;**69**:157-63.
- Henriques A, Lourenco AV, Ribeirinho A, Ferreira H, Graca LM. Maternal death related to misoprostol overdose. *Obstet. Gynecol.* 2007;**109**:489-90.
- Henshaw K, Finan LB. The accessibility of abortion services in the United States, 2001. *Perspectives on Sexual and Reproductive Health* 2003;**35**:16-24.

Hess RF. Women's stories of abortion in southern Gabon, Africa. *J.Transcult.Nurs.* 2007;**18**:41-8.

Ho PC. Women's perceptions on medical abortion. *Contraception* 2006;**74**:11-5.

Jermy K, Oyelese O, Bourne T. Uterine anomalies and failed surgical termination of pregnancy: the role of routine preoperative transvaginal sonography. *Ultrasound Obstet.Gynecol.* 1999;**14**:431-3.

Jewkes RK, Gumede T, Westaway MS, Dickson K, Brown H, Rees H. Why are women still aborting outside designated facilities in metropolitan South Africa? *BJOG.* 2005;**112**:1236-42.

Kiran U, Amin P, Penketh RJ. Self-administration of misoprostol for termination of pregnancy: safety and efficacy. *J.Obstet.Gynaecol.* 2004;**24**:155-6.

Lafaurie MM, Grossman D, Troncoso E, Billings DL, Chavez S. Women's perspectives on medical abortion in Mexico, Colombia, Ecuador and Peru: a qualitative study. *Reprod.Health Matters.* 2005;**13**:75-83.

Lara D, Abuabara K, Grossman D, Diaz-Olavarrieta C. Pharmacy provision of medical abortifacients in a Latin American city. *Contraception* 2006;**74**:394-9.

Lialios G, Kallitsaris A, Mademtzis J, Messinis IE. Uterine perforation as a rare complication of attempted pregnancy termination with misoprostol: a case report. *J.Reprod.Med.* 2006;**51**:599-600.

Lin SK, Ho ES, Chen YJ. Hematosalpinx: an unusual complication after medical abortion with oral mifepristone and misoprostol. *Ultrasound Obstet.Gynecol.* 2005;**25**:416-7.

Liu B, Sun J, Tao W. [The pathological investigations on termination of early pregnancy with mifepristone]. *Zhonghua Fu Chan Ke.Za Zhi.* 1995;**30**:7-9.

Lu S, Wu R, Wang Z. [Expression of T-lymphocytes and cytokines in the decidua of mifepristone with misoprostol for terminating early pregnancy]. *Zhonghua Fu Chan Ke.Za Zhi.* 2001;**36**:625-7.

Machtinger R, Goldenberg M, Soriano D, Zolti M, Atlas M, Seidman DS. [Medical termination of pregnancy with mifepristone--initial experience at the Sheba Medical Center]. *Harefuah* 2003;**142**:666-8, 719.

Mamers PM, Lavelle AL, Evans AJ, Bell SM, Rusden JR, Healy DL. Women's satisfaction with medical abortion with RU486. *Med.J.Aust.* 1997;**167**:316-7.

Marsollier C, Tailland ML, Courtieu C, Dechaud H, Mares P. [The use of sulprostone (Nalador) in the evacuation of uterine contents. Apropos of 32 cases at the Department

of Gynecology, University Hospital Center, Nimes, over 2 years (a retrospective study)]. *J.Gynecol.Obstet.Biol.Reprod.(Paris)* 1993;**22**:399-404.

Melgalve I, Lazdane G, Trapenciene I, Shannon C, Bracken H, Winikoff B. Knowledge and attitudes about abortion legislation and abortion methods among abortion clients in Latvia. *European Journal of Contraception and Reproductive Health Care* 2005;**10**:143-50.

Mendilcioglu I, Zorlu CG, Simsek M. Successful termination of a cervical pregnancy with misoprostol. *Eur.J.Obstet.Gynecol.Reprod.Biol.* 2003;**106**:96.

Mengue SS, Schenkel EP, Duncan BB, Schmidt MI. Prevalence and clinical correlates of unsuccessful use of drugs to induce menstruation. *Contraception* 1998;**57**:93-7.

Miller NH, Miller DJ, Pinkston Koenigs LM. Attitudes of the physician membership of the society for adolescent medicine toward medical abortions for adolescents. *Pediatrics* 1998;**101**:E4.

Misago C, Fonseca W, Correia L, Fernandes LM, Campbell O. Determinants of abortion among women admitted to hospitals in Fortaleza, North Eastern Brazil. *Int.J.Epidemiol.* 1998;**27**:833-9.

Nahar S, Rasul CH, Sayed A, Azim AK. Utility of misoprostol for labor induction in severe pre-eclampsia and eclampsia. *J.Obstet.Gynaecol.Res.* 2004;**30**:349-53.

Ngoc NTN, Winikoff B, Clark S, Ellertson C, Am KN, Hieu DT *et al.* Safety, efficacy and acceptability of mifepristone-misoprostol medical abortion in Vietnam. *International Family Planning Perspectives* 1999;**25**:10-+.

Olinto MT, Moreira Filho DC. [Estimating the frequency of induced abortion: a comparison of two methods]. *Rev.Panam.Salud Publica* 2004;**15**:331-6.

Olinto MTA, Moreira DD. Estimating the frequency of induced abortion: a comparison of two methods. *Revista Panamericana de Salud Publica-Pan American Journal of Public Health* 2004;**15**:331-6.

Osorio-de-Castro CG, Pepe VL, Luiza VL, Cosendey MA, Freitas AM, Miranda FF *et al.* [Prescribed and reported drug use during pregnancy]. *Cad.Saude Publica* 2004;**20 Suppl 1**:S73-S82.

Osuna E, Toucedo MA, Sanchez-Espigares G, Garfia A, Aparicio FJ, Rueda J *et al.* A case of self-inflicted wounding by the introduction of needles through the abdominal wall to induce abortion. *Forensic Science International* 2002;**128**:141-5.

Pastuszak AL, Schuler L, Speck-Martins CE, Coelho KE, Cordello SM, Vargas F *et al.* Use of misoprostol during pregnancy and Mobius' syndrome in infants. *N.Engl.J.Med.* 1998;**338**:1881-5.

- Petersen MB, Rorbye C, Nilas L. [Large variation in clinical regimens use to induce medical abortion in Denmark]. *Ugeskr.Laeger* 2003;**165**:2187-90.
- Prine L, Lesnewski R, Berley N, Gold M. Medical abortion in family practice: a case series. *J.Am.Board Fam.Pract.* 2003;**16**:290-5.
- Qiu X, Li D, Zhou X. [Study of histopathology of endometrium following termination of early pregnancy using mifepristone]. *Zhonghua Fu Chan Ke.Za Zhi.* 1999;**34**:272-4.
- Rademakers J, Koster E, Jansen-van Hees ACV, Willems F. Medical abortion as an alternative to vacuum aspiration: first experiences with the 'abortion pill' in The Netherlands. *European Journal of Contraception and Reproductive Health Care* 2001;**6**:185-91.
- Ramachandar L, Pelto PJ. Medical abortion in rural Tamil Nadu, South India: a quiet transformation. *Reprod.Health Matters.* 2005;**13**:54-64.
- Raymond E, Kaczorowski J, Smith P, Sellors J, Walsh A. Medical abortion and family physicians - Survey of residents and practitioners in two Ontario settings. *Canadian Family Physician* 2002;**48**:538-44.
- Remez L. Medical abortion regimen with reduced mifepristone dose, home misoprostol use is feasible and effective. *International Family Planning Perspectives* 2001;**27**:210-1.
- Rocha J. Brazil investigates drug's possible link with birth defects. *BMJ* 1994;**309**:757-8.
- Rosa RF, Travi GM, Valiatti F, Zen PR, Pinto LL, Kiss A *et al.* Poland syndrome associated with an aberrant subclavian artery and vascular abnormalities of the retina in a child exposed to misoprostol during pregnancy. *Birth Defects Res.A Clin.Mol.Teratol.* 2007;**79**:507-11.
- Rosing MA, Archbald CD. The knowledge, acceptability, and use of misoprostol for self-induced medical abortion in an urban US population. *J.Am.Med.Womens Assoc.* 2000;**55**:183-5.
- Schuler L, Pastuszak A, Sanseverino TV, Orioli IM, Brunoni D, Ashton-Prolla P *et al.* Pregnancy outcome after exposure to misoprostol in Brazil: a prospective, controlled study. *Reprod.Toxicol.* 1999;**13**:147-51.
- Schwendke A, Zarkadas M, Alder J, Horner E, Bitzer J, Holzgreve W. [Medical abortion with mifepristone and misoprostol: study of the efficacy, somatic tolerance and perception of medical abortion]. *Gynakol.Geburtshilfliche Rundsch.* 2002;**42**:225-33.

Simonds W, Ellertson C, Winikoff B, Springer K. Providers, pills and power: the US mifepristone abortion trials and caregivers' interpretations of clinical power dynamics. *Health* 2001;**5**:207-31.

Sina ED. The reduction in maternal mortality in Chile, 1990-200. *Revista Panamericana de Salud Publica-Pan American Journal of Public Health* 2004;**15**:326-30.

Sit D, Rothschild AJ, Creinin MD, Hanusa BH, Wisner KL. Psychiatric outcomes following medical and surgical abortion. *Hum.Reprod.* 2007;**22**:878-84.

Sorensen EC, Iversen OE, Bjorge L. Failed medical termination of twin pregnancy with mifepristone: a case report. *Contraception* 2005;**71**:231-3.

Tamang A, Tamang J. Availability and acceptability of medical abortion in Nepal: health care providers' perspectives. *Reprod.Health Matters.* 2005;**13**:110-9.

Tschudin S, Zanotelli D, Bitzer J, Holzgreve W. Experiences with medical abortion, in particular postabortion control, treatment in case of residuals and subsequent contraception. *Geburtshilfe und Frauenheilkunde* 2004;**64**:1299-304.

Van Bebber SL, Phillips KA, Weitz TA, Gould H, Stewart F. Patient costs for medication abortion: Results from a study of five clinical practices. *Womens Health Issues* 2006;**16**:4-13.

Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VF, Sugayama SM *et al.* Prenatal exposure to misoprostol and vascular disruption defects: a case-control study. *Am.J.Med.Genet.* 2000;**95**:302-6.

Virgo KS, Carr TR, Hile A, Virgo JM, Sullivan GM, Kaikati JG. Medical versus surgical abortion: A survey of knowledge and attitudes among abortion clinic patients. *Womens Health Issues* 1999;**9**:143-54.

Weng L, Jiao L, Tang X. [Histological study of uterine cervix during termination of early pregnancy by mifepristone and prostaglandins]. *Zhonghua Fu Chan Ke.Za Zhi.* 1995;**30**:522-5.

Wiebe ER, Switzer P. Arteriovenous malformations of the uterus associated with medical abortion. *Int.J.Gynaecol.Obstet.* 2000;**71**:155-8.

Wiebe ER. Misoprostol administration in medical abortion. A comparison of three regimens. *J.Reprod.Med.* 2001;**46**:125-9.

Winikoff B, Sivin I, Coyaji KJ, Cabezas E, Xiao BL, Gu SJ *et al.* The acceptability of medical abortion in China, Cuba and India. *International Family Planning Perspectives* 1997;**23**:73-&.

Cost-effectiveness

Creinin MD, Shore E, Balasubramanian S, Harwood B. The true cost differential between mifepristone and misoprostol and misoprostol-alone regimens for medical abortion. *Contraception* 2005;**71**:26-30.

Pharmacology

Blanchard K, Winikoff B, Ellertson C. Use of misoprostol during pregnancy and Mobius' syndrome in infants. *N.Engl.J.Med.* 1998;**339**:1553-4.

Castilla EE, Orioli IM. Teratogenicity of misoprostol: data from the Latin-American Collaborative Study of Congenital Malformations (ECLAMC). *Am.J.Med.Genet.* 1994;**51**:161-2.

Cronemberger MF, Castro Moreira JB, Brunoni D, Mendonca TS, Alvarenga EH, Rizzo AM *et al.* Ocular and clinical manifestations of Mobius' syndrome. *J.Pediatr.Ophthalmol.Strabismus* 2001;**38**:156-62.

da Silva DP, Knop FP, Mengue SS. Prenatal exposure to misoprostol and congenital anomalies: systematic review and meta-analysis. *Reprod.Toxicol.* 2006;**22**:666-71.

Dai M, Liu Q, Zi X, Peng D. [Effect of total glycoside from *Clinopodium polycephalum* on uterine bleeding quantity in drug abortion model rats]. *Zhong.Yao Cai.* 2002;**25**:342-4.

Danielsson KG, Swahn ML, Bygdeman M. Effect of Antiprogestin, Hcg and A Prostaglandin Analog on Human Uterine Contractility. *Contraception* 1993;**47**:295-301.

Fonseca W, Alencar AJ, Mota FS, Coelho HL. Misoprostol and congenital malformations. *Lancet* 1991;**338**:56.

Fontenelle L, Araujo APDC, Fontana RS. Moebius syndrome: case report. *Arquivos de Neuro-Psiquiatria* 2001;**59**:812-4.

Gemzell-Danielsson K, Bygdeman M, Aronsson A. Studies on uterine contractility following mifepristone and various routes of misoprostol. *Contraception* 2006;**74**:31-5.

Gonzalez CH, Marques-Dias MJ, Kim CA, Sugayama SM, Da Paz JA, Huson SM *et al.* Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. *Lancet* 1998;**351**:1624-7.

Gonzalez CH, Marques-Dias MJ, Kim CA, Paz JA, Sugayama SMM, Valente M. Misoprostol embryopathy: clinical evaluations of 13 patients with congenital hydrocephaly. *American Journal of Human Genetics* 2002;**71**:279.

Graf WD, Shepard TH. Uterine contraction in the development of Mobius syndrome. *J Child Neurol*. 1997;**12**:225-7.

Henriques A, Lourenco AV, Ribeirinho A, Ferreira H, Graca LM. Maternal death related to misoprostol overdose. *Obstet.Gynecol*. 2007;**109**:489-90.

Kruse B, Poppema S, Creinin MD, Paul M. Management of side effects and complications in medical abortion. *Am.J.Obstet.Gynecol*. 2000;**183**:S65-S75.

Marques-Dias MJ. Physiopathogeny of Moebius syndrome and arthrogriposis due to in utero misoprostol exposure. *Arquivos de Neuro-Psiquiatria* 2000;**58**:590.

Pastuszak AL, Schuler L, Speck-Martins CE, Coelho KE, Cordello SM, Vargas F *et al*. Use of misoprostol during pregnancy and Mobius' syndrome in infants. *N.Engl.J.Med*. 1998;**338**:1881-5.

Pastuszak AL, Schuler L. Use of misoprostol during pregnancy and Mobius' syndrome in infants - reply. *New England Journal of Medicine* 1998;**339**:1554.

Pohls UG, Steck T, Dietl J. Fetal complications associated with unsuccessful attempts at termination of pregnancy. *Zeitschrift fur Geburtshilfe und Neonatologie* 2000;**204**:153-7.

Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. *Contraception* 2005;**71**:22-5.

Shepard TH. Mobius syndrome after misoprostol: a possible teratogenic mechanism. *Lancet* 1995;**346**:780.

van Look PF, von Hertzen H. Misoprostol and birth defects. *BMJ* 1995;**310**:128.

Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VF, Sugayama SM *et al*. Prenatal exposure to misoprostol and vascular disruption defects: a case-control study. *Am.J.Med.Genet*. 2000;**95**:302-6.

Winikoff B. Clostridium sordellii infection in medical abortion. *Clin.Infect.Dis*. 2006;**43**:1447-8.

Winsor EJ, Windrim R, Chitayat D, Ryan G, Seaward G, Akoury H. Success rate for culture of fetal postmortem tissue is dependent on the method of pregnancy termination. *Fetal Diagn.Ther*. 2005;**20**:306-8.

Zou Y, Li YP, Lei ZW, Lu L, Jiang S, Li Q. [Side effect of mifepristone in combination with misoprostol for medical abortion]. *Zhonghua Fu Chan Ke.Za Zhi*. 2004;**39**:39-42.

Politics/ Licensing/ Ethics

Misoprostol and legal medical abortion. *Lancet* 1991;**338**:1241-2.

Medical abortion options may advance in 1998. *Contracept.Technol.Update*. 1997;**18**:149-50.

Cutting unsafe abortions. *Afr.Health* 1998;**20**:46.

New warning for mifepristone and misoprostol. *Lancet* 2005;**366**:344.

[Anon]. Urgent need for standardised misoprostol regimens. *Reproductive Health Matters* 2002;**10**:202.

Aubeny E. [Trends since 1989, in France, of induced abortions by mifepristone (RU486) combined with a prostaglandin analogue]. *Contracept.Fertil.Sex* 1997;**25**:777-81.

Barbosa RM, Arilha M. The Brazilian experience with Cytotec. *Stud.Fam.Plann*. 1993;**24**:236-40.

Berer M. Making abortions safe: a matter of good public health policy and practice. *Bulletin of the World Health Organization* 2000;**78**:580-92.

Brun J, Legernaes K. [Misoprostol for inducing abortion is often stopped on religious and legal reasons]. *Lakartidningen* 2006;**103**:4053.

Cohen J, Ortiz O, Llaguno SE, Goodyear L, Billings D, Martinez I. Reaching women with instructions on misoprostol use in a Latin American country. *Reprod.Health Matters*. 2005;**13**:84-92.

Costa SH. Commercial availability of misoprostol and induced abortion in Brazil. *Int.J.Gynaecol.Obstet*. 1998;**63 Suppl 1**:S131-S139.

Davey A. Mifepristone and prostaglandin for termination of pregnancy: contraindications for use, reasons and rationale. *Contraception* 2006;**74**:16-20.

De Costa CM. Medical abortion for Australian women: it's time. *Med.J.Aust*. 2005;**183**:378-80.

Friedman MA. Manufacturer's warning regarding unapproved uses of misoprostol. *N.Engl.J.Med*. 2001;**344**:61.

Goldman LA, Garcia SG, Diaz J, Yam EA. Brazilian obstetrician-gynecologists and abortion: a survey of knowledge, opinions and practices. *Reprod.Health* 2005;**2**:10.

Grimes DA. Unsafe abortion: the silent scourge. *Br.Med.Bull*. 2003;**67**:99-113.

- Grimes DA, Benson J, Singh S, Romero M, Ganatra B, Okonofua FE *et al.* Unsafe abortion: the preventable pandemic. *Lancet* 2006;**368**:1908-19.
- Grimes DA, Benson J, Singh S, Romero M, Ganatra B, Okonofua FE *et al.* Sexual and reproductive health 4 - Unsafe abortion: the preventable pandemic. *Lancet* 2006;**368**:1908-19.
- Iversen OE, Bergsjø P. [Should antiprogesterone be used in pregnancy termination?]. *Tidsskr.Nor Laegeforen.* 1998;**118**:212-3.
- Joffe C. Reactions to medical abortion among providers of surgical abortion: an early snapshot. *Fam.Plann.Perspect.* 1999;**31**:35-8.
- Joffe C. Roe v. Wade at 30: What are the prospects for abortion provision? *Perspectives on Sexual and Reproductive Health* 2003;**35**:29-33.
- Joffe C, Weitz TA. Normalizing the exceptional: incorporating the "abortion pill" into mainstream medicine. *Social Science & Medicine* 2003;**56**:2353-66.
- Kleiverda G. [First trimester medical abortion: a good method that is seldom used in The Netherlands]. *Ned.Tijdschr.Geneeskd.* 2006;**150**:766-9.
- Kolata G. U.S. may allow anti-ulcer drug tied to abortion. *NY Times (Print.)* 1988;1, 5.
- Lowenstein E, Wanzer SH. The U.S. Attorney General's intrusion into medical practice. *N.Engl.J.Med.* 2002;**346**:447-8.
- Melgalve I, Lazdane G, Trapenciene I, Shannon C, Bracken H, Winikoff B. Knowledge and attitudes about abortion legislation and abortion methods among abortion clients in Latvia. *European Journal of Contraception and Reproductive Health Care* 2005;**10**:143-50.
- Nash ES. Legal termination of pregnancy. *S.Afr.Med.J.* 2003;**93**:87.
- Nathanson BN. The abortion cocktail. *First.Things.* 1996;**59**:23-6.
- Pheterson G, Azize Y. Abortion practice in the northeast Caribbean: "Just write down stomach pain". *Reprod.Health Matters.* 2005;**13**:44-53.
- Pollack AE, Pine RN. Opening a door to safe abortion: international perspectives on medical abortifacient use. *J.Am.Med.Womens Assoc.* 2000;**55**:186-8.
- Rao KA, Faundes A. Access to safe abortion within the limits of the law. *Best Practice & Research in Clinical Obstetrics & Gynaecology* 2006;**20**:421-32.
- Singh S. Hospital admissions resulting from unsafe abortion: estimates from 13 developing countries. *Lancet* 2006;**368**:1887-92.

Editorials/ Letters/ Opinions

Misoprostol and legal medical abortion. *Lancet* 1991;**338**:1241-2.

Death after RU-486. *NY Times (Print.)* 2006;A22.

Aubeny E. [The efficacy and acceptability of voluntary interruption of pregnancy by medication without hospitalization in a city hospital: a prospective study of 433 patients]. *Gynecol.Obstet.Fertil.* 2005;**33**:727-8.

Baird DT, Norman JE, Thong KJ, Glasier AF. Misoprostol, mifepristone, and abortion. *Lancet* 1992;**339**:313.

Blanchard K, Winikoff B, Ellertson C. Use of misoprostol during pregnancy and Mobius' syndrome in infants. *N.Engl.J.Med.* 1998;**339**:1553-4.

Blinder V, Elul B, Winikoff B. Mifepristone-misoprostol medical abortion: who will use it and why? *Am.J.Obstet.Gynecol.* 1998;**179**:1376.

Castilla EE, Orioli IM. Teratogenicity of misoprostol: data from the Latin-American Collaborative Study of Congenital Malformations (ECLAMC). *Am.J.Med.Genet.* 1994;**51**:161-2.

Coelho HI, Misago C, da Fonseca WV, Sousa DS, de Araujo JM. Selling abortifacients over the counter in pharmacies in Fortaleza, Brazil. *Lancet* 1991;**338**:247.

da Silva DP, Tierling VL, Schuler-Faccin L, Sanseverino MT, Mengue SS. Reproductive results associated with misoprostol and other substances utilized for interruption of pregnancy. *Eur.J.Clin.Pharmacol.* 2005;**61**:71-2.

Darney PD. Deaths associated with medication abortion. *Contraception* 2005;**72**:319.

Downie WW. Misuse of misoprostol. *Lancet* 1991;**338**:247.

Fonseca W, Alencar AJ, Mota FS, Coelho HL. Misoprostol and congenital malformations. *Lancet* 1991;**338**:56.

Fonseca W, Misago C, Kanji N. Misoprostol plus mifepristone. *Lancet* 1991;**338**:1594.

Hassan T. Misoprostol (Cytotec). *Midwifery Today Int.Midwife.* 2001;67-8.

Hofmeyr GJ. Misoprostol in obstetrics and gynaecology--unregistered, dangerous and essential. *S.Afr.Med.J.* 1998;**88**:535-6.

Kilpatrick SJ. Perinatal morbidity associated with misoprostol-induced labor - Reply. *American Journal of Obstetrics and Gynecology* 2000;**182**:750.

Mohamedbhai AG, Hassan Miyan AM, Lacombe D. Neonatal Proteus syndrome?
Am.J.Med.Genet. 2002;**112**:228-30.

Pastuszak AL, Schuler L. Use of misoprostol during pregnancy and Mobius' syndrome in infants - reply. *New England Journal of Medicine* 1998;**339**:1554.

Schaff EA. Methotrexate and Misoprostol Are Effective in Inducing Abortion.
American Family Physician 1995;**52**:2341.

Schuler L, Ashton PW, Sanseverino MT. Teratogenicity of misoprostol. *Lancet* 1992;**339**:437.

Shepard TH. Mobius syndrome after misoprostol: a possible teratogenic mechanism.
Lancet 1995;**346**:780.

Sicard D, Chauvelot-Moachon L. Comment: pathophysiology of mifepristone-induced septic shock due to *Clostridium sordellii*. *Ann.Pharmacother.* 2005;**39**:2142-3.

Ulmann A. Warning on low dose mifepristone use. *Pharmacoeconomics.* 1994;**6**:90.

van Look PF, von Hertzen H. Misoprostol and birth defects. *BMJ* 1995;**310**:128.

Zahradnik HP. Misuse of Misoprostol for Inducing Abortion. *Deutsche Medizinische Wochenschrift* 1992;**117**:1735-6.

Unspecified

Methotrexate and misoprostol for abortion. *Med.Lett.Drugs Ther.* 1996;**38**:39-40.

Options expand in wait for mifepristone arrival. *Contracept.Technol.Update.* 1998;**19**:158-60.

Mifepristone (RU 486). *Med.Lett.Drugs Ther.* 2000;**42**:101-2.

Althaus F. Misoprostol alone is not a highly effective medical abortion regimen, but it rarely causes side effects. *International Family Planning Perspectives* 1996;**22**:133-4.

Chavkin W. Topics for our times: Public health on the line - Abortion and beyond.
American Journal of Public Health 1996;**86**:1204-6.

Couzin J. infectious disease. RU-486-linked deaths open debate about risky bacteria.
Science 2006;**312**:986.

Ewart WR, Winikoff B. Toward safe and effective medical abortion. *Science* 1998;**281**:520-1.

Faucher P. [Acceptability of misoprostol at home for voluntary drug-induced abortion. *Gynecol Obstet Fertil* 2004; 32 : 26-33]. *Gynecol.Obstet.Fertil.* 2004;**32**:472-3.

Filippini A, Villa G, Corrocher R, De Franceschi L. Acute Hemolytic Anemia With Acanthocytosis Associated With High-Dose Misoprostol for Medical Abortion. *Ann.Emerg.Med.* 2006.

Gehred GA. Abortion procedure. *J.Fam.Pract.* 1997;**45**:194.

Haimov-Kochman R, Sciaky-Tamir Y, Arbel R, Brzezinski A, Laufer N, Yagel S. Is ultrasound evaluation following medical abortion with mifegine and misoprostol necessary? *Journal of the Society for Gynecologic Investigation* 2004;**11**:321A.

Kolata G. Any sale in U.S. of abortion pill still years away. *NY Times (Print.)* 1988;1, 26.

Nilas L, Ottesen BS. [Should early abortion be treated medically?]. *Ugeskr.Laeger* 2006;**168**:293-4.

Okonofua F. Misoprostol and women's health in Africa. *Afr.J.Reprod.Health* 2005;**9**:7-3.

Orr RD, Larimore WL. Medical abortion is not just a medical issue. *American Family Physician* 1997;**56**:351-&.

Rouzi AA. Complications of self-induced medical abortion with misoprostol. *Saudi.Med.J.* 2003;**24**:228.

Schneider AP. Abortion procedure. *J.Fam.Pract.* 1997;**45**:193.

Schonhofar PS. Brazil: misuse of misoprostol as an abortifacient may induce malformations. *Lancet* 1991;**337**:1534-5.

Winikoff B, Davis AR. Abortion is for women. *Lancet* 2007;**369**:1904-6.